Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity
— BMB proprietary 5-HT2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency — — Effect of BMB compounds was consistent with other anti-epileptics such as fenfluramine — Vancouver, BC – August 18, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG)…
